CELU
Closed
Celularity Inc
2.05
+0.09 (+4.59%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.96
Day's Range: 1.96 - 2.2612
Send
sign up or login to leave a comment!
When Written:
0.6197
Celularity Inc is a biotechnology company that specializes in developing and commercializing innovative cellular therapies for the treatment of cancer, infectious diseases, and degenerative disorders. The company was founded in 2017 by Dr. Robert Hariri, a leading stem cell scientist, and entrepreneur, and is headquartered in Florham Park, New Jersey.
Celularity's core technology platform is based on the use of placental-derived cells, which are abundant, easy to collect, and possess unique regenerative properties. The company's product pipeline includes several cell-based therapies, including CYNK-001, a natural killer (NK) cell therapy for the treatment of cancer; CVM-1118, a stem cell therapy for the treatment of acute respiratory distress syndrome (ARDS); and CMC-100, a cell therapy for the treatment of COVID-19.
In addition to its therapeutic programs, Celularity is also developing a range of diagnostic tools and biomarker assays to help identify patients who are most likely to benefit from its cell-based therapies. The company has partnerships with several leading academic and research institutions, including the University of California, San Diego, and the University of Texas MD Anderson Cancer Center.
Celularity has raised more than $500 million in funding to date from a range of investors, including SoftBank Vision Fund, United Therapeutics, and Sorrento Therapeutics. The company is led by a team of experienced executives with deep expertise in biotechnology, healthcare, and finance.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Celularity's core technology platform is based on the use of placental-derived cells, which are abundant, easy to collect, and possess unique regenerative properties. The company's product pipeline includes several cell-based therapies, including CYNK-001, a natural killer (NK) cell therapy for the treatment of cancer; CVM-1118, a stem cell therapy for the treatment of acute respiratory distress syndrome (ARDS); and CMC-100, a cell therapy for the treatment of COVID-19.
In addition to its therapeutic programs, Celularity is also developing a range of diagnostic tools and biomarker assays to help identify patients who are most likely to benefit from its cell-based therapies. The company has partnerships with several leading academic and research institutions, including the University of California, San Diego, and the University of Texas MD Anderson Cancer Center.
Celularity has raised more than $500 million in funding to date from a range of investors, including SoftBank Vision Fund, United Therapeutics, and Sorrento Therapeutics. The company is led by a team of experienced executives with deep expertise in biotechnology, healthcare, and finance.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!